FireFly Metals Ltd (ASX:FFM, TSX:FFM, OTC:MNXMF) reported a highly productive quarter marked by strong drilling results at the Green Bay Copper-Gold Project in Newfoundland and steady progress toward an upscaled production restart. The company said consistently high-grade intersections have extended known mineralisation ahead of a December-quarter Mineral Resource Estimate (MRE) update, with initial outputs from economic studies expected early next year.
The quarter was highlighted by four pillars:
Imugene Ltd (ASX:IMU, OTC:IUGNF) has reported encouraging early efficacy data from the CAR T-naïve portion of its ongoing Phase 1b trial of azer-cel (azercabtagene zapreleucel) — an off-the-shelf, allogeneic CD19 CAR T-cell therapy being tested across multiple B-cell lymphoma types.
Of six evaluable patients with no prior CAR T treatment, five (83%) achieved an overall response, including three (50%) complete responses. Results from a sixth patient are pending. Ten patients have been treated so far in this cohort, spanning several rare and difficult-to-treat lymphoma subtypes such as Waldenström macroglobulinemia, marginal zone lymphoma and primary CNS lymphoma — areas where no CAR T therapies are currently approved.
NextSource Materials Inc. (TSX:NEXT, OTCQB:NSRCF) said on Wednesday it has extended its drawdown credit facility with Vision Blue Resources Limited by up to an additional US$10 million, providing the graphite producer with greater financial flexibility as it advances its battery anode facility in the UAE.
The new funding increases the total potential size of the facility to US$30 million.
Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF) shares jumped on Wednesday after UBS almost tripled its share price target, citing accelerating demand for the company’s solid oxide fuel cell (SOFC) technology and an improving financial outlook.
The target was lifted to 350p from 120p and a 'buy' rating, with shares in the company rising 16% on the day to 306p, up around 300% since Bosch pulled out of its partnership in February.
Trust Stamp Inc (NASDAQ:IDAI, EURONEXT:AIID), a global provider of AI-powered privacy enhancing technologies (PETs), has joined Founders Arena, a startup accelerator focused on the WealthTech sector, as part of its strategy to expand into wealth management.
Trust Stamp president Andrew Gowasack said the company, which has already reached 100 financial institutions, is now targeting wealth managers, who face fraud risks similar to those in banking and insurance.
Northstar Gold Corp. (CSE:NSG) has announced plans for non-brokered private placements to fund permitting, engineering, and the initial implementation of Novamera’s Surgical Mining system at its 100%-owned Cam Copper Project, located 18 kilometres southeast of Kirkland Lake, Ontario.
The financing will provide initial capital for the Cam Copper Zone 2 Surgical Mining pilot program, under a definitive Turnkey Surgical Mining Services Agreement signed with Novamera in October.
NEXE Innovations Inc (TSX-V:NEXE, OTC:NEXNF) announced that it has received a repeat purchase order for approximately 250,000 of its BPI-certified compostable coffee pods from a North American office coffee services (OCS) and retail distributor.
The new order follows a previous delivery of 80,000 compostable coffee pods for three new SKUs last week, the company said on Wednesday.
Medicus Pharma (NASDAQ:MDCX) has partnered with the Gorlin Syndrome Alliance (GSA) to expand compassionate access to its investigational microneedle therapy, SKINJECT, for patients suffering from Gorlin Syndrome, a rare genetic condition that causes recurring skin cancers.
Under the collaboration, the two groups will pursue an Expanded Access Investigational New Drug (IND) program with the US Food and Drug Administration (FDA) to allow patients with multiple or inoperable basal cell carcinomas (BCCs) to receive SKINJECT under physician supervision.
Standard Uranium Ltd (TSX-V:STND, OTCQB:STTDF) announced that it has closed the final tranche of its non-brokered private placement, raising gross proceeds of C$1,513,500.
When combined with earlier tranches, the uranium exploration company has raised gross proceeds of C$3,337,400 by issuing 15,598,750 non-flow-through (NFT) units, at a price of C$0.08 per NFT unit, and 20,895,000 flow-through (FT) units at a price of C$0.10 per FT unit.
Artemis Resources Ltd (ASX:ARV, AIM:ARV, OTCQB:ARTTF) shares surged 14% to 0.43p in London, after the company reported a standout intercept from first drilling at its Titan East prospect in Western Australia.
The initial reverse-circulation hole testing an interpreted shear zone returned 5m at 13.1g/t gold from 132m, including 3m at 20.9g/t from 133m, within a 20m mineralised interval.
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares climbed as much as 8% in early trading after the biotech company said US regulators had cleared its experimental CAR-T therapy for leukaemia to move to a higher dose level in its ongoing Phase I trial.
The independent Data Safety Monitoring Board, which oversees the study, reviewed safety data from the first three adult patients treated with Hemogenyx’s HG-CT-1 therapy for relapsed or refractory acute myeloid leukaemia and found no dose-limiting toxicities. As a result, the trial can now advance to the next dose cohort.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) has struck a development deal with a leading Japanese carmaker to build advanced driver and passenger monitoring systems, as the UK-listed technology company deepens its presence in Asia’s automotive market.
The company said on Wednesday that it had been chosen to deliver an “Advanced Development Project” directly with the manufacturer.
80 Mile PLC (AIM:80M, OTCQB:BLLYF) shares rose almost 10% after the company saw its run of positive news continue.
The latest catalyst came in the form of an announcement from its US joint venture partners regarding an independent assessment and prospective resources report that set out the "world-class potential" of the Jameson land basin in Eastern Greenland.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) shares rose 9% to 94.47p after the mining royalty company reported record third-quarter earnings, fuelled by surging income from its copper and cobalt assets and the resumption of mining at its Kestrel coal royalty area.
Total portfolio contribution, Ecora’s measure of royalty and streaming income, more than doubled to $25 million in the three months to September, from $11.8 million in the previous quarter.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has wiped out its shareholder debt and strengthened its finances after investors exercised £55 million worth of warrants and agreed to a fresh £50 million loan facility running through to 2030.
The AIM-listed biotechnology company, which develops allergy vaccines and treatments, said on Wednesday that its long-term backers SkyGem Acquisition and Southern Fox Investments had exercised 1.38 billion warrants issued under a 2023 funding agreement.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) reported a record quarter, lifted by a surge in revenue from its copper and cobalt interests, as the London-listed royalty company continues to benefit from the global demand for metals used in clean energy technology.
The company said total portfolio contribution, its measure of income from royalties and metal streams, more than doubled to $25 million in the three months to the end of September, up from $11.8 million in the previous quarter.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported encouraging one-year clinical outcomes from its DurAVR® Transcatheter Heart Valve (THV) in patients with small aortic annuli, demonstrating durable hemodynamic performance and excellent safety results.
The data, drawn from 65 patients treated under the ongoing EMBARK and US Early Feasibility studies, showed sustained single-digit mean pressure gradients and large effective orifice areas (EOAs) after one year. Notably, no valve-related mortality or moderate/severe paravalvular leaks were observed.
Elixir Energy Ltd (ASX:EXR, OTC:ELXPF) has provided a Queensland operations update covering its Taroom Trough and broader Surat–Bowen Basin activities, confirming it will resume operatorship of the Diona-1 permit upon JV formalisation and is planning multi-stage stimulation and production testing for execution this quarter. For Lorelle-3, Elixir has agreed terms to use the H&P FlexRig 648 — specifically imported by Shell for its Taroom Trough appraisal — secured land access and long-lead items with civil works to commence shortly, and locked in the high-impact appraisal well for drilling in January 2026.
